Smaller Baskets, Bigger Questions: How Weight Loss Drugs Are Redefining the Consumer Products CEO Profile

Of all the forces restructuring the consumer products sector in 2026, none is creating more pressure on the corner office than a class of pharmaceutical drugs that most CPS executives never expected to be part of their commercial agenda.

GLP-1 receptor agonists, the drug class that includes Ozempic, Wegovy, and Mounjaro, were originally developed to treat type 2 diabetes. Their appetite-suppressing effects made them the fastest-growing pharmaceutical category in modern history, and their secondary effects on how consumers eat, shop, and think about food are now landing squarely on the desks of CPS leaders who were, for the most part, not hired to manage anything like this. The question boards should be sitting with is whether the executive criteria they use to evaluate, develop, and hire CPS leaders have kept pace with what the GLP-1 era demands. 

The Scale of the Disruption, Properly Read

The numbers around GLP-1 adoption are large enough that they deserve to be read carefully rather than cited loosely. As of late 2025, 23% of US households already have at least one member on a GLP-1 medication, and new patient prescriptions grew 16% between September 2024 and September 2025, representing an additional 2.9 million scripts in a single year. And the addressable population is about to expand significantly further, because the FDA approved the first oral GLP-1 formulation at the end of 2025, removing the barrier of weekly injections that has kept many potential users from starting treatment. JPMorgan projects upwards of 30 million Americans on GLP-1 treatment by 2030, and Circana’s research projects that households with at least one GLP-1 user will account for 35% of all US food and beverage units sold by that same year. 

Those adoption figures are important because of what they produce in consumer behavior. A Cornell University study published in the Journal of Marketing Research found that GLP-1 users reduced household grocery spending by an average of 5.3% within six months of starting treatment, with spending on savory snacks falling approximately 10% and similar declines in sweets, baked goods, and cookies. PwC’s consumer research of roughly 3,000 people found that GLP-1 users spent about 11% less on most food categories overall, and at the scale of adoption now underway, those individual household changes aggregate into the revenue reduction JPMorgan estimates at between $30 billion and $55 billion for the food and beverage industry by 2030 to 2034. 

The part of the picture that tends to get lost in that revenue figure is that GLP-1 users do not stop buying food but instead redirect spending toward protein-rich, fiber-dense, smaller-format products rather than exiting the grocery store altogether, and Circana’s data confirms that GLP-1 households still outspend non-users on a per-household basis. The CPS company that reads GLP-1 adoption as a pure volume threat is reading only half the picture, and the half it is missing is where the opportunity sits. 

The Portfolio Decisions No One Wants to Make

Understanding the aggregate numbers is the easier part of this challenge. The harder part is what they require of CPS executives at the level of their own specific portfolios, because not every company faces the same exposure and not every category carries the same risk. A portfolio concentrated in savory snacks, baked goods, sugary beverages, and calorie-dense convenience food occupies a materially different position from one weighted toward protein products, functional foods, and nutrient-dense formats, and that difference in exposure has grown more pronounced with every quarter of adoption data since 2024. 

The companies that understand their specific exposure now, at the category and SKU level, are the ones with time to reposition before the pressure becomes visible in the income statement. The ones waiting for the trend to become undeniable are ceding that window, and Circana’s analysis adds a further layer of urgency: the categories with the steepest GLP-1 spending declines are often the same categories with the most bloated SKU counts, the result of years of incremental product extensions that made sense when volume was growing but become expensive to maintain as demand contracts. The GLP-1 era is therefore accelerating portfolio discipline decisions that many companies were already overdue to make, which means the question is not really whether to rationalize but whether to do it on the company’s own terms or under duress. 

Making these decisions requires an executive who can hold the commercial tension between protecting near-term revenue and making resource allocation decisions that the data says are necessary, which is not the same skill as growing a category in a tailwind. It requires the willingness to act on an uncomfortable forward-looking view before the income statement forces the issue, and a board that understands the difference between decisive portfolio management and short-term underperformance. 

A New Skillset the Traditional CPS Career Path Did Not Build

The consumer products sector has historically produced its chief executives through a clear pathway: brand management, then category leadership, then P&L ownership. That pathway optimized for executives who understood distribution, shelf execution, retailer relationships, and consumer marketing, and it produced a generation of leaders exceptionally well-suited to growing volume in established categories with known consumer profiles. The GLP-1 era does not invalidate those capabilities, but it requires something additional that the traditional pathway rarely develops. 

The executives responding most effectively to GLP-1 disruption are conversant with health science at a meaningful level, not in terms of marketing claims but in terms of understanding what happens to appetite, satiety, and food preference over a GLP-1 treatment period, what the data says about consumption patterns after discontinuation, and how those patterns affect demand planning across a portfolio. Because that understanding needs to translate into commercial decisions, they also engage directly with innovation and R&D functions around product reformulation, not as a brand exercise but as a response to measurable changes in what their consumers can comfortably consume. And because the regulatory environment around GLP-1 access is still changing, they track developments like access expansion and the approval of new oral formulations as commercially relevant intelligence rather than background news. 

They are also comfortable making decisions from granular data that their predecessors rarely needed to access. PwC’s research notes that food and beverage companies with a highly concentrated customer base face the most acute exposure and should be closely examining GLP-1 uptake rates within their specific consumer segments. Knowing not just who your consumer is today but which segments of your consumer base are most likely to be on GLP-1 drugs within three years requires a leader who thinks in consumer health terms, not only in category terms, and that kind of thinking is not something most CPS career paths have historically rewarded. 

What This Means for Executive Assessment and Succession Planning

The leadership profile that GLP-1 disruption demands is not the one most CPS succession pipelines were built to develop, and that mismatch creates an assessment problem for boards. When evaluating sitting executives on their GLP-1 preparedness, the meaningful questions go beyond awareness, because awareness without action is not leadership. Has the executive commissioned an analysis of their portfolio’s exposure by segment and geography? Have they made any changes to product development priorities in response to the data? Have they engaged their board on the revenue implications at a level of specificity that goes beyond general commentary? An executive who can talk fluently about GLP-1 in broad terms but has not translated that fluency into concrete decisions is watching rather than leading. 

For external search, the competency framing needs to be updated to reflect what this moment requires. Health science literacy, meaning the ability to engage substantively with nutrition, physiology, and pharmaceutical data and convert that engagement into commercial decisions, should be an explicit criterion in CPS CEO mandates where portfolio exposure is material. However, it’s important to note that this not a request for a medical background. Rather, it is a request for intellectual curiosity, the habit of engaging with domains outside the conventional CPS toolkit, and a track record of acting on what that engagement reveals. The most relevant experience to look for in candidates is not just previous CPS leadership but evidence that they have successfully managed a business through demand discontinuity, a moment when the underlying consumer behavior model stopped working and required a complete rethinking of the commercial model rather than incremental optimization. GLP-1 adoption is that kind of moment for portions of the sector, and the executives who have dealt with comparable situations elsewhere, whether in food, health and wellness, or adjacent consumer categories, bring a pattern of judgment worth more than another decade of volume management in a stable category. 

M&A as an Innovation Shortcut, and What It Demands of Leaders

The honest assessment for many CPS companies is that reformulating or repositioning their way through GLP-1 disruption from within their own R&D and innovation functions will take longer than the market will wait. That reality is creating significant M&A logic in the sector, particularly around targets that already have credibility in protein, functional nutrition, digestive health, and portion-controlled premium formats, because acquiring a company that is already winning with the GLP-1 consumer compresses a timeline that organic innovation cannot. 

There are broadly three paths companies are taking. Nestlé’s launch of Vital Pursuit, a frozen meal brand developed specifically for GLP-1 users, represents internal innovation built around the new consumer profile. ConAgra’s decision to label 26 Healthy Choice products as GLP-1-friendly represents repositioning existing assets. The third path, acquiring companies that are already winning with the GLP-1 consumer, compresses the timeline and is increasingly attractive as a result, with a protein snack brand or functional beverage company commanding considerably more value in this environment than its revenue multiple would have suggested two years ago. 

CPS leaders evaluating acquisition targets without GLP-1 alignment as an explicit screening criterion are missing one of the more consequential value drivers in the sector right now. Beyond the deal itself, however, this raises a talent question that boards often address too late. Post-acquisition integration of a health and wellness brand into a traditional CPS holding requires executives who can credibly lead businesses with very different consumer relationships, innovation cultures, and distribution models, and the leader who is excellent at traditional grocery execution may be exactly the wrong person to run a functional nutrition acquisition. Boards need to be thinking about this before they sign the deal, not after. 

Leading Through Structural Disruption Without Retreating Into It

There is a temptation, when facing the kind of demand disruption that GLP-1 represents, to treat it as existential and respond with wholesale portfolio transformation, but that response carries its own risks. The majority of consumer food spending is not disappearing, and PwC’s research is clear that while GLP-1 users reduce overall food spending, they do not exit the grocery store. They prioritize differently, which means the most defensible position is not abandoning affected categories entirely but understanding with precision which parts of those categories can be reformulated or repositioned for the GLP-1 consumer, which cannot, and making honest decisions about each. 

The truth is that pharmaceutical upheaval in the consumer products sector was not on most CPS strategy maps five years ago. It is now one of the more consequential business developments in the sector, and it is selecting for a different kind of executive than the one who might have succeeded in the category management era. The companies that recognize this early, and build or hire for the capabilities it demands, will find opportunity where most of their peers see only threat. For boards and search committees, the starting point is an honest audit of whether the leadership profile they are developing and recruiting for was built for the world that used to exist, or the one that is arriving. 

Stanton Chase’s Consumer Products and Services practice works with boards and leadership teams across the CPS sector to identify and secure the executive talent needed to lead through disruption.  

About the Author

Milos Tucakovic is a Managing Partner at Stanton Chase Belgrade. He is also Stanton Chase’s Consumer Products and Services Global Sector Leader. He brings 20 years of executive search expertise and nearly 40 years of experience in human resources and management. A licensed A&DC Assessor, Miloš also coaches CEOs and General Managers on leadership development. Miloš is a member of the Knowledge Committee of Serbia and previously taught management at the Academy of Applied Studies – College of Hotel Management in Belgrade for 16 years. 

Dietrich Hauffe, Ph.D. is a Partner at Stanton Chase Düsseldorf and Global Sector Leader for Life Sciences and Healthcare. With a doctorate in biochemistry and years of experience in biotech leadership, Dietrich specializes in executive searches for the analytical industry, biotechnology, biopharmaceuticals, diagnostics, and medical devices. His expertise extends to functional areas including marketing and sales, R&D, operations, and medical affairs. Having spent over a decade in the U.S.A. and Canada, Dietrich brings a truly international perspective to his work in the biotech industry.